Chikungunya is a mosquito-borne viral disease — caused by chikungunya virus (CHIKV) and transmitted by Aedes aegypti and Aedes albopictus mosquitoes. It causes sudden fever, severe joint pain (polyarthritis), headache, muscle pain, nausea and rash. Named from the Makonde language meaning "that which bends up" — reflecting the stooped posture from severe arthritis. Though rarely fatal, chikungunya causes profound disability from arthritis that can persist for months to years.

How does chikungunya differ from dengue?

Both are Aedes-transmitted arboviruses causing febrile illness and co-circulate in the same areas, making clinical distinction difficult. Key differences: Chikungunya causes more severe joint pain (polyarthritis — affecting multiple joints, often symmetric); dengue causes more severe bone pain ("breakbone fever") and thrombocytopenia with higher bleeding risk. Dengue more commonly causes severe shock (DHF/DSS) and is associated with higher mortality. Rash is common in both. Laboratory confirmation is required for definitive diagnosis.

What is the Ixchiq vaccine?

Ixchiq (VLA1553, Valneva/Bavarian Nordic) — FDA approved November 2023 — is the world's first licensed chikungunya vaccine. It is a single-dose live attenuated vaccine for adults ≥18 years. Clinical trial data showed immunogenicity (neutralising antibody response) in approximately 98% of vaccinees at day 28; vaccine seroresponse was durable through the study period. Contraindicated in immunocompromised individuals and pregnant women (live vaccine). Recommended for: travellers to endemic regions; adults living in high-risk areas where vaccine is available.

What is chronic chikungunya?

The most debilitating aspect of chikungunya is chronic arthritis — joint pain and swelling persisting more than 3 months after the acute illness (in approximately 10-40% of cases). Affected joints: wrists, ankles, knees, shoulders, fingers — often symmetric and migratory. This chronic arthritis can persist for 1-2+ years in some patients, causing significant disability. Risk factors: older age, pre-existing joint disease, high acute viral load. Management: NSAIDs initially; physiotherapy; in severe persistent cases, hydroxychloroquine or methotrexate (limited evidence).

Is chikungunya present in Europe?

Yes — Aedes albopictus (tiger mosquito), established in southern Europe (Italy, France, Spain, Greece and spreading), has enabled autochthonous chikungunya transmission in Europe: Italy 2007 (197 cases — the first major European outbreak from a single imported case); France 2017, 2022 (multiple clusters). Climate change is expanding Ae. albopictus range northward. ECDC continuously monitors chikungunya risk in Europe. Any traveller returning from an endemic area with fever and arthralgia should be tested for chikungunya.

How is chikungunya diagnosed?

During the febrile phase (0-7 days): RT-PCR for CHIKV RNA (the most sensitive and specific test). After the febrile phase: CHIKV IgM antibodies appear by days 5-7 and persist for months; CHIKV IgG for past infection. ELISA IgM/IgG are the standard serological tests. A positive CHIKV IgM in the appropriate clinical and epidemiological context is diagnostic.

How does GMJ News cover chikungunya?

GMJ News covers WHO chikungunya outbreak alerts, Ixchiq vaccine approval, ECDC European risk monitoring, Brazil and Latin America outbreak data, and chronic arthritis management. Chikungunya — transmitted by the increasingly prevalent Aedes albopictus — is a growing concern for the Caucasus region.

Home › Topics › Chikungunya

Chikungunya

GMJ News knowledge hub · last reviewed September 2026 · Georgian Medical Journal

Summary Statistics Glossary GMJ news FAQ Documents Organizations Research

Chikungunya — caused by chikungunya virus (CHIKV) transmitted by Aedes mosquitoes — has infected over 115 million people across 115 countries and territories and is rapidly re-emerging as a major global health threat: the 2023 outbreak in Brazil alone caused nearly 300,000 cases, and WHO declared chikungunya a priority outbreak in 2023 (WHO). Named from the Makonde word meaning “that which bends up” — from the characteristic stooped posture caused by debilitating polyarthritis — chikungunya causes a distinct syndrome of fever, rash and severe joint pain that can persist for months to years. Ixchiq (VLA1553) — approved by FDA in November 2023 — is the first licensed chikungunya vaccine, a landmark in arboviral disease prevention.

Key messages

115 countries affected — Ixchiq vaccine 2023

Chikungunya virus has affected 115+ countries. The FDA approved Ixchiq — the first licensed chikungunya vaccine — in November 2023, a landmark in arboviral prevention.

Debilitating polyarthritis

Chikungunya causes severe bilateral polyarthritis affecting small and large joints — often more debilitating than dengue. Joint pain can persist for months to years (chronic chikungunya arthritis), causing long-term disability.

Two mosquito vectors

Transmitted by Aedes aegypti (tropical) and Aedes albopictus (tiger mosquito — temperate climates, spreading globally with climate change). Aedes albopictus has enabled chikungunya to spread into Europe (Italy 2007, France 2017, 2022).

2023 emergency outbreaks

WHO declared chikungunya a priority outbreak in 2023. Brazil experienced a massive outbreak (highest burden ever); Paraguay declared a health emergency. India, Pakistan and the Philippines also experienced significant outbreaks.

No approved antiviral

Treatment is supportive: rest, fluids, NSAIDs or paracetamol for fever and pain. No approved antiviral. Aspirin is avoided. Chloroquine has been studied but shows no benefit.

Vector control is primary prevention

Eliminating Aedes breeding sites (standing water — tires, flower pots, containers), using insect repellent, wearing protective clothing and screening are the primary prevention strategies until vaccine deployment scales.

Key statistics

115+

countries/territories with chikungunya transmission

WHO

~300K

cases in Brazil in 2023 outbreak (WHO emergency)

PAHO/WHO 2023

Nov 2023

Ixchiq (first chikungunya vaccine) FDA approval

FDA/Valneva

1-12mth

typical duration of chronic chikungunya arthritis

WHO

<1%

case fatality rate (higher in elderly, neonates, immunocompromised)

WHO

1952

year chikungunya first identified (Tanzania)

WHO/History

Chikungunya — global cumulative affected countries and territories by region — WHO

Source: WHO. Rapid global spread via Aedes albopictus into temperate zones with climate change.

Glossary of key terms

Chikungunya virus (CHIKV)
WHOA positive-sense RNA alphavirus (Togaviridae) — transmitted by Aedes mosquitoes. Three genotypes: Asian, East/Central/South African (ECSA), West African. The 2004-2007 pandemic wave used a mutant ECSA strain with enhanced replication in Aedes albopictus.

Aedes albopictus (tiger mosquito)
WHO/ECDCAn invasive Aedes mosquito — smaller and less aggressive than Ae. aegypti but with broader geographic range (tolerates cooler climates). Now established in southern Europe, North America, East Asia and increasingly invasive globally with climate change. Competent vector for chikungunya, dengue and Zika.

Ixchiq (VLA1553)
FDA 2023/ValnevaThe first licensed chikungunya vaccine — a live attenuated single-dose vaccine, FDA approved November 2023 for adults ≥18 years. Provides approximately 100-day immunogenicity protection in trials. Named after the Mayan moon goddess of medicine.

Chronic chikungunya arthritis
WHO/RheumatologyPersistent joint pain/arthritis lasting more than 3 months after acute chikungunya — affecting approximately 10-40% of patients. Can mimic rheumatoid arthritis. Risk factors: older age, pre-existing arthritis, high viral load. Managed with NSAIDs, physiotherapy; occasionally methotrexate or hydroxychloroquine for severe persistent cases.

Neonatal chikungunya
WHOVertical transmission from viraemic mother to neonate during delivery — not transplacental (rare). Neonatal chikungunya is severe: encephalopathy, haemorrhagic manifestations, high mortality. Caesarean section does not prevent transmission. Mothers with fever near delivery should be screened.

ECSA lineage mutation (E1:A226V)
ResearchA mutation in the CHIKV envelope protein E1 (alanine to valine at position 226) that emerged in 2006 — dramatically enhancing viral replication efficiency in Aedes albopictus (previously a poor vector). This mutation enabled the 2007 Reunion Island/Indian Ocean epidemic and subsequent spread to India and beyond via Ae. albopictus.